Effect of bovine lactoferrin on recurrent urinary tract infections: in vitro and in vivo evidences
Authors:
- 29 June 2022
- journal article
- research article
- Published by Springer Nature in BioMetals
- Vol. 36 (3) , 491-507
Abstract
Uropathogenic Escherichia coli (UPEC) strains are the primary cause of urinary tract infections (UTIs). UPEC strains are able to invade, multiply and persisting in host cells. Therefore, UPEC strains are associated to recurrent UTIs requiring long‐term antibiotic therapy. However, this therapy is suboptimal due to the increase of multidrug-resistant UPEC. The use of non-antibiotic treatments for managing UTIs is required. Among these, bovine lactoferrin (bLf), a multifunctional cationic glycoprotein, could be a promising tool because inhibits the entry into the host cells of several intracellular bacteria. Here, we demonstrate that 100 μg/ml bLf hinders the invasion of 2.0 ± 0.5 × 104 CFU/ml E. coli CFT073, prototype of UPEC, infecting 2.0 ± 0.5 × 105 cells/ml urinary bladder T24 epithelial cells. The highest protection (100%) is due to the bLf binding with host surface components even if an additional binding to bacterial surface components cannot be excluded. Of note, in the absence of bLf, UPEC survives and multiplies, while bLf significantly decreases bacterial intracellular survival. After these encouraging results, an observational survey on thirty-three patients affected by recurrent cystitis was performed. The treatment consisted in the oral administration of bLf alone or in combination with antibiotics and/or probiotics. After the observation period, a marked reduction of cystitis episodes was observed (p < 0.001) in all patients compared to the episodes occurred during the 6 months preceding the bLf-treatment. Twenty-nine patients did not report cystitis episodes (87.9%) whereas the remaining four (12.1%) experienced only one episode, indicating that bLf could be a worthwhile and safe treatment in counteracting recurrent cystitis.Keywords
This publication has 65 references indexed in Scilit:
- Lead Optimization Studies on FimH Antagonists: Discovery of Potent and Orally Bioavailable Ortho-Substituted Biphenyl MannosidesJournal of Medicinal Chemistry, 2012
- VFDB 2012 update: toward the genetic diversity and molecular evolution of bacterial virulence factorsNucleic Acids Research, 2011
- Urinary tract infections in women: etiology and treatment optionsInternational Journal of General Medicine, 2011
- Persistence of Uropathogenic Escherichia coli in the Face of Multiple AntibioticsAntimicrobial Agents and Chemotherapy, 2010
- Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: A randomized controlled trialScandinavian Journal of Primary Health Care, 2009
- The N1 Domain of Human Lactoferrin Is Required for Internalization by Caco-2 Cells and Targeting to the NucleusBiochemistry, 2008
- Effect of bovine lactoferricin on enteropathogenic Yersinia adhesion and invasion in HEp-2 cellsJournal of Medical Microbiology, 2004
- Lactoferrin against Staphylococcus aureus MastitisVeterinary Immunology and Immunopathology, 2003
- Lactoferrin Inhibits the Lipopolysaccharide-Induced Expression and Proteoglycan-Binding Ability of Interleukin-8 in Human Endothelial CellsInfection and Immunity, 2002
- Characterization of the lactoferrin‐dependent inhibition of the adhesion of Actinobacilllus actinomycetemcomitans, Prevotella intermedia and Prevotella nigrescens to fibroblasts and to a reconstituted basement membraneAPMIS, 1997